touchEXPERT OPINIONS New and emerging strategies for managing patients with relapsed/refractory follicular lymphoma: latest advances in prognostics and treatment
Watch leading lymphoma specialists provide updates on prognostic factors and novel treatment strategies for patients with relapsed/refractory follicular lymphoma
How can we best utilize prognostic factors to identify patients with FL at risk of the poorest outcomes?
Prof. Maddocks describes the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
1/3 Next InterviewInterview Questions
In this interview, Prof. Maddocks answers the following questions:
- What are the key prognostic scoring systems used at initial diagnosis of FL and what are their advantages versus limitations?
- How is PET/CT used prior to treatment of FL and how might measurement of total metabolic tumor volume aid prognosis?
- What are the key parameters used as prognostic factors after initial treatment of FL?
- Based on ongoing research into novel prognostic factors for FL, what key parameters may have prognostic value in future clinical practice?
- How can the way prognosis is assessed in patients with FL be improved upon in future?
About Prof. Kami Maddocks
Dr Kami Maddocks is a Professor of Clinical Internal Medicine and Director of the Lymphoma Program in the Division of Hematology at The Ohio State University. She works as a hematologist specializing in treating patients with B-cell malignancies, including non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and chronic lymphocytic leukemia. Dr Maddocks conducts research on new therapies for these hematologic malignancies, largely through evaluating new targeted therapies in clinical trials. She has particular interest in aggressive lymphomas, including mantle cell lymphoma (MCL).read more
Dr Maddocks received her medical degree from the University of South Dakota, followed by an internal medicine internship and residency at Mayo Clinic Rochester, Minnesota. She completed her fellowship in hematology/oncology at The Ohio State University. She has board certification in internal medicine, medical oncology and hematology.
Dr Maddocks is an investigator on several clinical trials in lymphoma, most of which are evaluating non-chemotherapeutic approaches to the treatment of lymphoma. She serves on the Alliance Lymphoma Committee, a multi-institution working group to develop clinical trials in lymphoma and she is the Alliance Chair on two MCL trials through Alliance Foundation Trials and National Clinical Trials Network. Over the years, Dr Maddocks has been very involved with philanthropic efforts through the Leukemia and Lymphoma Society and Pelotonia.
Professor Kami Maddocks discloses: Research funding from Bristol Myers Squibb, Merck, Novartis and Pharmacyclics. Consulting fees from ADC Therapeutics, Beigene, Celgene, Janssen, Karyopharm, Kite, Morphosys, Pharmacyclics and Seattle Genetics.
With novel treatments now available and several in development, is there new hope for patients with R/R FL?
Dr Batlevi reviews the novel and emerging treatment strategies for patients with R/R FL
2/3 Next InterviewInterview Questions
In this interview, Dr Batlevi answers the following questions:
- What new approaches to the treatment of patients with R/R FL have emerged in recent years?
- What PI3K inhibitors are available for the treatment of R/R FL and how do they differ?
- Why is EZH2 an attractive target for FL therapy and what EZH2 inhibitors are available?
- Why are CD19 CAR T cells promising emerging therapies for R/R FL and what are the key agents in development?
About Dr Connie Lee Batlevi
Connie Lee Batlevi, MD, PhD, is a Medical Oncologist at Memorial Sloan Kettering Cancer Centre in New York, USA. She received her medical degree from the University of Massachusetts Medical School and completed an Internal Medicine residency at Mount Sinai Hospital/Mount Sinai School of Medicine. She completed her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. She has board certification in internal medicine and oncology.read more
At Memorial Sloan Kettering Cancer Centre, Dr Batlevi treats lymphoma via a variety of techniques, including chemotherapy, immunotherapy, targeted therapy, radiotherapy and stem cell transplantation. She also conducts lymphoma research as part of a team of world-class lymphoma experts who have more than 100 years of combined experience and a shared goal of providing the most effective, personalized care for people with the disease. Dr Batlevi’s research focuses on lymphoma genetics, mechanism-based therapies for targeted therapy, and the application of CAR T cells in the treatment of lymphoma, and she is currently involved in a number of clinical trials investigating immunotherapy, new drug combinations, and biomarker-based targeted therapies.
Dr Connie Lee Batlevi discloses: Research funding from Bayer, Epizyme, Janssen, Novartis and Xynomic Pharmaceuticals. Consulting and advisory board fees from Juno Therapeutics/Celgene, Kite, LifeSci Capital, LLC and Seattle Genetics. Honorarium from Dava Oncology.
What is the latest clinical evidence for EZH2 and PI3K inhibitors in patients with R/R FL and how can we translate it into clinical practice?
Dr Sehn explains the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL and describes its potential implications for daily clinical practice
3/3 Take CME TestInterview Questions
In this interview, Dr Sehn answers the following questions:
- What is the latest clinical evidence for use of the EZH2 inhibitor tazemetostat in patients with R/R FL?
- What do the long-term follow-up data from the CHRONOS-1 study tell us about use of the PI3K inhibitor copanlisib in patients with R/R FL?
- In the recent DYNAMO study, what were the efficacy and safety results for the PI3K inhibitor duvelisib in the R/R FL patient subset?
- What is the ZEUS study and what value might its results have for patients with refractory FL treated with the PI3K inhibitor idelalisib?
- What are the practical implications of the efficacy and safety data for EZH2 and PI3K inhibitors in patients with R/R FL?
About Dr Laurie Sehn
Laurie Sehn is currently Clinical Professor with BC Cancer and University of British Columbia, Canada. She has been a medical oncologist and clinical investigator at BC Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA.read more
She was trained in hematology–oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University. Prior to returning to Canada, she spent a year at the Dana-Farber Cancer Institute with the Bone Marrow Transplant service.
Dr Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. She has also served as a member of the Editorial Board of Journal of Clinical Oncology and Leukemia Lymphoma, and is currently an Associate Editor for Blood. Dr Sehn also serves as Co-Chair of the Lymphoma Site of the Canadian Cancer Trials Group.
Dr Laurie Sehn discloses: Consulting fees and honoraria from AbbVie, Acerta, Amgen, Apobiologix, AstraZeneca, Celgene, Gilead, Incyte, Janssen, Karyopharm, Kite, Lundbeck, Merck, Morphosys, Roche/Genentech, Sandoz, Seattle Genetics, Takeda, Teva, TG Therapeutics and Verastem
Research funding from Teva.
Overview & Learning Objectives
Overview
In this activity, leading lymphoma specialists provide updates on the different prognostic indices and factors and novel treatment strategies, such as PI3K and EZH2 inhibition, for patients with relapsed/refractory follicular lymphoma.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
Target Audience
This activity has been designed to meet the educational needs of hematologists and oncologists involved in the management of follicular lymphoma.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Content Reviewer
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 29 March 2021. Date credits expire: 29 March 2022.
Learning Objectives
After watching this activity, participants should be better able to:
- Evaluate the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
- Evaluate novel and emerging treatment strategies for patients with R/R FL
- Translate the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL into clinical practice
Register to touchONCOLOGY for FREE
- Peer reviewed journals and expert opinion
- Interactive CME and e-learning modules
- Video conference highlights
